Search

Displaying results 1241 - 1250 of 5383 in total
  1. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022. … [A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  3. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.

  4. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label]. … Approved in May 2011 by the FDA, Incivek was indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Biomed 101

    go.drugbank.com/drugs/DB05851
    Investigational

    Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity. … Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.

  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]

  7. Drug

    Diatrizoate

    go.drugbank.com/drugs/DB00271
    ApprovedVet approved

    A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.

    Mixtures: Hypaque-M Liq 76% USP, Hypaque-M Liq 76% USP
  8. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  9. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)

  10. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … The latter indication was presented by Pernix Therapeutics.[L5974]